On June 1, 2023, Ashkan Abbey, MD, dosed the first patient in the Phase II SIGLEC Trial, a clinical study evaluating AVD-104, a potential new treatment for geographic atrophy (GA) from age-related
Lori Hastings and Tina Bell serve as the clinical research coordinators for our Fort Worth office, managing the enrollment and participation of patients in our clinical trials. These studies explore promising new